Robert Hodgkinson Acquires 75,000 Shares of VentriPoint Diagnostics Ltd. (CVE:VPT) Stock

VentriPoint Diagnostics Ltd. (CVE:VPT) Director Robert Hodgkinson bought 75,000 shares of the stock in a transaction dated Monday, April 22nd. The shares were purchased at an average cost of C$0.21 per share, for a total transaction of C$15,900.00.

Robert Hodgkinson also recently made the following trade(s):

• On Thursday, April 18th, Robert Hodgkinson bought 36,500 shares of VentriPoint Diagnostics stock. The shares were purchased at an average cost of C$0.21 per share, for a total transaction of C$7,774.50.

VentriPoint Diagnostics Price Performance

Shares of CVE:VPT opened at C$0.22 on Wednesday. The company has a quick ratio of 6.67, a current ratio of 2.06 and a debt-to-equity ratio of 32.61. VentriPoint Diagnostics Ltd. has a twelve month low of C$0.12 and a twelve month high of C$0.36. The stock’s 50 day moving average is C$0.25 and its 200-day moving average is C$0.24. The firm has a market capitalization of C$34.50 million, a price-to-earnings ratio of -7.33 and a beta of 0.39.

About VentriPoint Diagnostics

Ventripoint Diagnostics Ltd., a medical device company, engages in the development and commercialization of diagnostic tools that monitor patients with heart disease worldwide. The company offers Ventripoint Medical System (VMS), a medical imaging system that is used to generate three-dimensional models with critical volume and functional measurements of a patient's heart chambers; VMS+ software for use in creating three-dimensional model that generates accurate heart volumetric measurements.